{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:00:14Z","timestamp":1785297614836,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015969","name":"Fay Fuller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR-12206-17"],"award-info":[{"award-number":["SCOR-12206-17"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008717","name":"Sylvia and Charles Viertel Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1042589"],"award-info":[{"award-number":["1042589"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1071945"],"award-info":[{"award-number":["1071945"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1156693"],"award-info":[{"award-number":["1156693"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1162954"],"award-info":[{"award-number":["1162954"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004267","name":"Royal Adelaide Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1s CA184464"],"award-info":[{"award-number":["RO1s CA184464"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA194264"],"award-info":[{"award-number":["CA194264"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.neo.2021.11.009","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T18:58:27Z","timestamp":1637693907000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition"],"prefix":"10.1016","volume":"24","author":[{"given":"Melissa K.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5296-7614","authenticated-orcid":false,"given":"Manjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7045-1198","authenticated-orcid":false,"given":"Melinda N.","family":"Tea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Pitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5135-6504","authenticated-orcid":false,"given":"John","family":"Toubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-6616","authenticated-orcid":false,"given":"Paul P.-S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dovile","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-7082","authenticated-orcid":false,"given":"Darren J.","family":"Creek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briony L.","family":"Gliddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-5937","authenticated-orcid":false,"given":"Craig T.","family":"Wallington-Beddoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-2740","authenticated-orcid":false,"given":"Stuart M.","family":"Pitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2021.11.009_bib0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clinic proceedings"},{"key":"10.1016\/j.neo.2021.11.009_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph8010001","article-title":"Clinical use of proteasome inhibitors in the treatment of multiple myeloma","volume":"8","author":"Merin","year":"2014","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neo.2021.11.009_bib0003","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.neo.2021.11.009_bib0004","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"Journal of cellular and molecular medicine"},{"key":"10.1016\/j.neo.2021.11.009_bib0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","article-title":"Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma","volume":"12","author":"Vincenz","year":"2013","journal-title":"Molecular cancer therapeutics"},{"key":"10.1016\/j.neo.2021.11.009_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The unfolded protein response and cell fate control","volume":"69","author":"Hetz","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.neo.2021.11.009_bib0007","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1209235","article-title":"Road to ruin: targeting proteins for degradation in the endoplasmic reticulum","volume":"334","author":"Smith","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neo.2021.11.009_bib0008","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","article-title":"The mammalian unfolded protein response","volume":"74","author":"Schroder","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.neo.2021.11.009_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2017.00078","article-title":"Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate","volume":"7","author":"Corazzari","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.neo.2021.11.009_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neo.2021.11.009_bib0011","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neo.2021.11.009_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2021.11.009_bib0013","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/fon.11.42","article-title":"Carfilzomib: a novel second-generation proteasome inhibitor","volume":"7","author":"Khan","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.neo.2021.11.009_bib0014","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.bbalip.2013.12.013","article-title":"Evolving concepts in cancer therapy through targeting sphingolipid metabolism","volume":"1841","author":"Truman","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.neo.2021.11.009_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tibs.2010.08.001","article-title":"Regulation of sphingosine kinase and sphingolipid signaling","volume":"36","author":"Pitson","year":"2011","journal-title":"Trends in biochemical sciences"},{"key":"10.1016\/j.neo.2021.11.009_bib0016","doi-asserted-by":"crossref","first-page":"43602","DOI":"10.18632\/oncotarget.17115","article-title":"Sphingosine kinase 2 inhibition synergises with bortezomib to target multiple myeloma by enhancing endoplasmic reticulum stress","volume":"8","author":"Wallington-Beddoe","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2021.11.009_bib0017","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.neo.2021.11.009_bib0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.14525","article-title":"RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neo.2021.11.009_bib0019","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/BF02634350","article-title":"Mycoplasma detection by PCR analysis","volume":"29","author":"Hopert","year":"1993","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.neo.2021.11.009_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neo.2021.11.009_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neo.2021.11.009_bib0022","series-title":"Statistical Genomics: Methods in Molecular Biology","first-page":"391","article-title":"It's DE-licious: A recipe for differential expression analyses of RNA-seq experiments using quasi-likelihood methods in edgeR","author":"Lun","year":"2016"},{"key":"10.1016\/j.neo.2021.11.009_bib0023","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsdottir","year":"2013","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.neo.2021.11.009_bib0024","article-title":"Haplotype-based variant detection from short-read sequencing","author":"Garrison","year":"2012","journal-title":"arXiv"},{"key":"10.1016\/j.neo.2021.11.009_bib0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.neo.2021.11.009_bib0026","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2021.11.009_bib0027","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/acs.jmedchem.5b01439","article-title":"From sphingosine kinase to dihydroceramide desaturase: A structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II)","volume":"59","author":"Aurelio","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.neo.2021.11.009_bib0028","doi-asserted-by":"crossref","first-page":"e56471","DOI":"10.1371\/journal.pone.0056471","article-title":"Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2021.11.009_bib0029","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: a useful in vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.neo.2021.11.009_bib0030","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","author":"Barrio","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2021.11.009_bib0031","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.neo.2021.11.009_bib0032","doi-asserted-by":"crossref","first-page":"29854","DOI":"10.1074\/jbc.M115.664953","article-title":"The nuclear factor (erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myeloma","volume":"290","author":"Li","year":"2015","journal-title":"The Journal of biological chemistry"},{"key":"10.1016\/j.neo.2021.11.009_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010033","article-title":"Activation of serum\/glucocorticoid regulated kinase 1\/nuclear factor-kappaB pathway are correlated with low sensitivity to bortezomib and ixazomib in resistant multiple myeloma cells","volume":"9","author":"Tsubaki","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.neo.2021.11.009_bib0034","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.neo.2021.11.009_bib0035","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.bbalip.2019.06.002","article-title":"Sphingolipids and the unfolded protein response","volume":"1864","author":"Bennett","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.neo.2021.11.009_bib0036","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neo.2021.11.009_bib0037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/leu.2016.186","article-title":"Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study","volume":"31","author":"Moreau","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2021.11.009_bib0038","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1242\/jcs.026062","article-title":"Initiation and execution of lipotoxic ER stress in pancreatic beta-cells","volume":"121","author":"Cunha","year":"2008","journal-title":"J Cell Sci"},{"key":"10.1016\/j.neo.2021.11.009_bib0039","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature09968","article-title":"Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity","volume":"473","author":"Fu","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neo.2021.11.009_bib0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BJ20101867","article-title":"A lipidomic screen of palmitate-treated MIN6 beta-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking","volume":"435","author":"Boslem","year":"2011","journal-title":"The Biochemical journal"},{"key":"10.1016\/j.neo.2021.11.009_bib0041","doi-asserted-by":"crossref","first-page":"26569","DOI":"10.1074\/jbc.M113.489310","article-title":"Alteration of endoplasmic reticulum lipid rafts contributes to lipotoxicity in pancreatic beta-cells","volume":"288","author":"Boslem","year":"2013","journal-title":"The Journal of biological chemistry"},{"key":"10.1016\/j.neo.2021.11.009_bib0042","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1091\/mbc.e11-04-0295","article-title":"Membrane aberracy and unfolded proteins activate the endoplasmic reticulum stress sensor Ire1 in different ways","volume":"22","author":"Promlek","year":"2011","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.neo.2021.11.009_bib0043","doi-asserted-by":"crossref","first-page":"E2271","DOI":"10.1073\/pnas.1318262111","article-title":"Activation of the endoplasmic reticulum unfolded protein response by lipid disequilibrium without disturbed proteostasis in vivo","volume":"111","author":"Hou","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2021.11.009_bib0044","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.1217611110","article-title":"Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains","volume":"110","author":"Volmer","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neo.2021.11.009_bib0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.molcel.2017.06.012","article-title":"Activation of the unfolded protein response by lipid bilayer stress","volume":"67","author":"Halbleib","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.neo.2021.11.009_bib0046","doi-asserted-by":"crossref","first-page":"37118","DOI":"10.1074\/jbc.M502207200","article-title":"SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism","volume":"280","author":"Maceyka","year":"2005","journal-title":"The Journal of biological chemistry"},{"key":"10.1016\/j.neo.2021.11.009_bib0047","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013326","article-title":"Sphingolipid homeostasis in the endoplasmic reticulum and beyond","volume":"5","author":"Breslow","year":"2013","journal-title":"Cold Spring Harbor perspectives in biology"},{"key":"10.1016\/j.neo.2021.11.009_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphingolipid metabolism: from synthesis to breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.neo.2021.11.009_bib0049","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.devcel.2018.04.023","article-title":"The UPR activator ATF6 responds to proteotoxic and lipotoxic stress by distinct mechanisms","volume":"46","author":"Tam","year":"2018","journal-title":"Dev Cell"},{"key":"10.1016\/j.neo.2021.11.009_bib0050","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.18632\/oncotarget.3178","article-title":"A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties","volume":"6","author":"Pitman","year":"2015","journal-title":"Oncotarget"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:08:08Z","timestamp":1761484088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558621000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1476558621000993"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2021.11.009","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}